title: The value of routine BMD monitoring after starting bisphosphonate treatment.
authors.forename: Katy J L
authors.initials: KJ
authors.lastname: Bell
authors.forename: Andrew
authors.initials: A
authors.lastname: Hayen
authors.forename: Les
authors.initials: L
authors.lastname: Irwig
authors.forename: Petra
authors.initials: P
authors.lastname: Macaskill
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Craig
authors.forename: Kristine E
authors.initials: KE
authors.lastname: Ensrud
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Bauer
mesh_terms: D015519:Bone Density / Q000502:physiology*; D004164:Diphosphonates / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000188:drug therapy; D006801:Humans; D008991:Monitoring, Physiologic; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D004164:Diphosphonates